Starting December 2016 Lipigon joins the AZ BioVentureHub located at AstraZeneca's site in Mölndal, Sweden. The contract stretches over 1 year giving Lipigon an office and full access to the whole facility, including infrastructure and capabilities.


Lipigon is happy to announce 3 new major partners investing in the company. Umeå based Fort Knox Förvaltning AB (Owner of Balticgruppen) and Partnerinvest Övre Norrland AB together with Antaros Medical AB in Gothenburg have entered as new shareholders. The investments allow for Lipigon to expand within present programs and to evaluate novel targets.


Lipigon Pharmaceuticals today announced that it has entered into a research collaboration with AstraZeneca to conduct joint research to identify drug candidates that promote the stabilization of Lipoprotein Lipase (LPL) and may have utility in the treatment of lipid disorders and cardiovascular disease.


21 juni, 2022, Pressmeddelande

Lipigon tillförs 22,6 MSEK i emissionslikvid

Lipigon Pharmaceuticals AB (publ) ("Bolaget" eller "Lipigon") meddelar härmed utfallet i den företrä...

13 juni, 2022, Pressmeddelande

Lipigons vd om emissionen och den nystartade fas I-studien

Lipigon beslutade i maj om en nyemission av aktier om drygt 21 MSEK med företrädesrätt för Lipigons ...

9 juni, 2022, Pressmeddelande

Ny studie: Leverspecifik behandling mot målproteinet ANGPTL4 är effektiv och säker

Hämning av målproteinet ANGPTL4 sänker triglycerid- och glukosnivåerna i blodet. Genom målsökande be...

9 juni, 2022, Pressmeddelande

New study: Liver-specific treatment of target protein ANGPTL4 is effective and safe

Inhibition of the target protein ANGPTL4 lowers triglyceride and glucose levels in the blood, accord...